Valuation: MannKind Corporation

Market Cap 1.28B 1.12B 1.04B 956M 1.8B 123B 1.82B 12.38B 4.84B 60.41B 4.79B 4.69B 209B P/E 2026 *
-222x
P/E 2027 * 26.4x
Enterprise Value 1.28B 1.12B 1.04B 956M 1.8B 123B 1.82B 12.38B 4.84B 60.41B 4.79B 4.69B 209B EV / Sales 2026 *
2.76x
EV / Sales 2027 * 2.44x
Free-Float
98.46%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: MannKind Corporation

1 day+6.17%
1 week+2.48%
Current month-3.05%
1 month+7.55%
3 months+52.96%
6 months-24.36%
Current year-27.16%
1 week 3.71
Extreme 3.7101
4.23
1 month 3.71
Extreme 3.7101
4.55
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 24/05/2017
Director of Finance/CFO 50 21/04/2024
Chief Tech/Sci/R&D Officer - 28/09/2025
Director TitleAgeSince
Director/Board Member 82 30/09/2003
Director/Board Member 82 30/11/2003
Chairman 69 08/12/2020
Date Insider Type Main position Quantity % Market Cap.
17/07/26 Sell

General Counsel

-24,109 0.0078%
17/07/26 Sell

Director

-52,485 0.0170%
15/07/26 Tax

Chief Financial Officer

-22,247 0.0072%
Change 5-day change 1-year change 3-year change Capi.($)
+6.17%+2.48%+1.23%-6.77% 1.2B
+0.93%+6.97%+62.83%+67.97% 56.67B
-1.92%+6.03%+43.68%+84.56% 55.92B
-0.46%-1.29%+3.28%+422.58% 23.28B
-2.97%-2.35%-22.03%-16.54% 23.28B
-0.36%+5.73%+30.99%-3.58% 20.54B
-1.34%+0.51%+25.02%-30.27% 17.78B
-1.44%+5.67%+32.54%+544.11% 15.9B
-1.30%-5.02%+165.62%+291.37% 14.64B
-0.50%-0.98%+23.62%+178.38% 13.99B
Average -0.32%+0.24%+36.68%+153.18% 24.32B
Weighted average by Cap. -0.85%+1.19%+40.80%+134.97%

Financials

2026 *2027 *
Net sales 462M 406M 378M 347M 651M 44.54B 661M 4.49B 1.75B 21.9B 1.74B 1.7B 75.71B 524M 460M 428M 393M 738M 50.43B 749M 5.08B 1.98B 24.79B 1.97B 1.92B 85.73B
Net income 72K 63.24K 58.81K 53.97K 101K 6.93M 103K 698K 273K 3.41M 270K 264K 11.79M 56.82M 49.91M 46.41M 42.59M 80.02M 5.47B 81.25M 551M 215M 2.69B 213M 209M 9.3B
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
24/07/26 US$4.130 +6.17% 9,439,893
23/07/26 US$3.890 +1.30% 2,941,996
22/07/26 US$3.840 -5.19% 5,543,073
21/07/26 US$4.050 +1.76% 4,403,386
20/07/26 US$3.980 -1.24% 3,024,894
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.130USD
Average target price
7.719USD
Spread / Average Target
+86.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNKD Stock